Neurocrine Bio. (NBIX) PT Raised to $163 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Price: $145.87 +2.22%
Rating Summary:
31 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 4 | New: 1
Rating Summary:
31 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 4 | New: 1
Join SI Premium – FREE
Morgan Stanley analyst Jeffrey Hung raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $163.00 (from $158.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia
- Ramelius Resources (RMS:AU) (RMLRF) PT Raised to AUD5.80 at UBS
- Vinci (DG:FP) (VCISY) PT Lowered to EUR135 at Berenberg
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
